World Pharma News

Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 9 min 26 sec ago

Johnson & Johnson initiates pivotal global Phase 3 clinical trial of Janssen's COVID-19 vaccine candidate

Mon, 09/28/2020 - 12:00
Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company's Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.

Strong activation of anti-bacterial T cells linked to severe COVID-19

Mon, 09/28/2020 - 10:00
A type of anti-bacterial T cells, so-called MAIT cells, are strongly activated in people with moderate to severe COVID-19 disease, according to a study by researchers at Karolinska Institutet in Sweden that is published in the journal Science Immunology. The findings contribute to increased understanding about how our immune system responds against COVID-19 infection.

Adequate levels of vitamin D reduces complications, death among COVID-19 patients

Fri, 09/25/2020 - 10:00
Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a significant decreased risk for adverse clinical outcomes including becoming unconscious, hypoxia (body starved for oxygen) and death.

Scientists trace severe COVID-19 to faulty genes and an autoimmune condition

Thu, 09/24/2020 - 12:00
More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new research shows. Another 3.5 percent, at least, carry a specific kind of genetic mutation.

In both groups, the upshot is basically the same: The patients lack type I interferon, a set of 17 proteins crucial for protecting cells and the body from viruses.

Reuters Events' Cell & Gene Therapy USA

Thu, 09/24/2020 - 10:00
2 November 2020, Virtual Event, USA.
Join 2500+ gene and cell therapy leaders for this (free to attend) conference brough to you by Reuters Events.

The race to commercialize cell & gene therapies (CGT) is heating up. Almost all of top 20 pharma have dedicated strategies, while US policy makers and the FDA are facilitating innovation and accelerating pathways to market.

Johns Hopkins researchers publish COVID-19 'prediction model'

Wed, 09/23/2020 - 12:00
Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today published a "prediction model" they say can help other hospitals care for COVID-19 patients - and make important decisions about planning and resource allocations.

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

Wed, 09/23/2020 - 10:00
Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021.

Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, said: "Today's announcement showcases our unwavering commitment to develop a COVID-19 vaccine that is available to everyone when it comes to market.

Web resources bring new insight into COVID-19

Tue, 09/22/2020 - 12:00
Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Baylor College of Medicine and the University of California San Diego. The resources are freely available through the Signaling Pathways Project (Baylor) and the Network Data Exchange (UCSD).

Total health: Build a better healthcare system

Tue, 09/22/2020 - 10:00
19 - 20 November, 2020. Digital Forum, #REhealthcare.
The stage is set for a paradigm shift in healthcare. The opportunity exists to redefine healthcare in a way that transforms patient outcomes, drives efficiency and changes lives.

Reuters Events Total Health will unite CEOs, innovators, disruptors and policy makers from across the healthcare ecosystem to seize upon this critical moment.

Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX facility

Mon, 09/21/2020 - 12:00
64 higher income economies have joined the COVAX Facility, a global initiative that brings together governments and manufacturers to ensure eventual COVID-19 vaccines reach those in greatest need, whoever they are and wherever they live. These 64 economies include commitments from 35 economies as well as the European Commission which will procure doses on behalf of 27 EU member states plus Norway and Iceland.

Researchers uncover early results about an existing tuberculosis vaccine that has been hypothesized to help against the coronavirus

Mon, 09/21/2020 - 10:00
While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widespread BCG vaccination appear to be weathering the pandemic better than their counterparts. This has led many researchers to suspect that BCG vaccine, which immunizes against tuberculosis, might offer protection against COVID-19.

Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union

Fri, 09/18/2020 - 22:20
Sanofi and GSK finalized and signed today an Advanced purchase agreement with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine, once the vaccine is approved. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established adjuvant technology.

Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies

Thu, 09/17/2020 - 10:00
Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies. Lilly is currently studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination.

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

Wed, 09/16/2020 - 12:00
Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of COVID-19. The latest study by researchers at La Jolla Institute for Immunology clearly argues in favor of the immune system.

Designed antiviral proteins inhibit SARS-CoV-2 in the lab

Wed, 09/16/2020 - 10:00
Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.

Progress toward antiviral treatments for COVID-19

Tue, 09/15/2020 - 12:00
COVID-19 is caused by a virus known as SARS-CoV-2, which is similar in structure to two other viruses that have caused recent outbreaks: SARS-CoV, which caused an outbreak of SARS in 2003, and MERS-CoV, the cause of a 2012 outbreak of Middle East Respiratory Syndrome.

Tiny antibody component highly effective against SARS-COV-2 in animal studies

Tue, 09/15/2020 - 10:00
University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19. This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drug - known as Ab8 - for potential use as a therapeutic and prophylactic against SARS-CoV-2.

Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial

Mon, 09/14/2020 - 12:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.

Which immune response could cause a vaccine against COVID-19?

Mon, 09/14/2020 - 10:00
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition. It is especially important now when multiple vaccines against COVID-19 are being developed. The top immunologists analyse types of immune response to predict what kind of vaccine would be the best.

COVID-19 vaccine AZD1222 clinical trials resumed in the UK

Sat, 09/12/2020 - 10:00
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators. The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume.